- Home
- HOUS vs CELC Comparison
HOUS vs CELC Comparison
Compare HOUS & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOUS
- CELC
- Stock Information
- Founded
- HOUS 2006
- CELC 2011
- Country
- HOUS United States
- CELC United States
- Employees
- HOUS N/A
- CELC N/A
- Industry
- HOUS Real Estate
- CELC Medical Specialities
- Sector
- HOUS Finance
- CELC Health Care
- Exchange
- HOUS Nasdaq
- CELC Nasdaq
- Market Cap
- HOUS 456.2M
- CELC 440.0M
- IPO Year
- HOUS 2006
- CELC 2017
- Fundamental
- Price
- HOUS $4.49
- CELC $39.91
- Analyst Decision
- HOUS Sell
- CELC Strong Buy
- Analyst Count
- HOUS 2
- CELC 6
- Target Price
- HOUS $4.00
- CELC $39.67
- AVG Volume (30 Days)
- HOUS 1.4M
- CELC 2.4M
- Earning Date
- HOUS 07-29-2025
- CELC 08-13-2025
- Dividend Yield
- HOUS N/A
- CELC N/A
- EPS Growth
- HOUS N/A
- CELC N/A
- EPS
- HOUS N/A
- CELC N/A
- Revenue
- HOUS $5,783,000,000.00
- CELC N/A
- Revenue This Year
- HOUS $5.38
- CELC N/A
- Revenue Next Year
- HOUS $6.22
- CELC N/A
- P/E Ratio
- HOUS N/A
- CELC N/A
- Revenue Growth
- HOUS 2.74
- CELC N/A
- 52 Week Low
- HOUS $2.71
- CELC $7.58
- 52 Week High
- HOUS $5.95
- CELC $46.42
- Technical
- Relative Strength Index (RSI)
- HOUS 55.29
- CELC 91.78
- Support Level
- HOUS $4.40
- CELC $34.30
- Resistance Level
- HOUS $5.25
- CELC $46.42
- Average True Range (ATR)
- HOUS 0.30
- CELC 2.40
- MACD
- HOUS 0.02
- CELC 2.96
- Stochastic Oscillator
- HOUS 46.48
- CELC 80.31
About HOUS Anywhere Real Estate Inc.
Anywhere Real Estate Inc operates in residential real estate, focusing on brokerage, relocation, title, settlement businesses, and mortgage and title insurance ventures. It supports approximately 1 million home sale sides annually. Brands include Better Homes and Gardens, CENTURY 21, Coldwell Banker, Corcoran, ERA, and Sotheby's International Realty. Revenue comes mainly from existing home transactions. Operations are segmented into Anywhere Brands (franchises), Anywhere Advisors (owned brokerage), and Anywhere Integrated Services (title and settlement).
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.